An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
The findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, are interim results from the NEOPRISM-CRC phase II clinical trial assessing whether the immunotherapy drug pembrolizumab can improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. The trial was a collaboration between UCL, UCLH, the Christie NHS Foundation Trust in Manchester, St. James’s University Hospital in Leeds, University Hospital Southampton and the University of Glasgow.
Bowel cancer is the fourth most common cancer in the UK, with around 42,900 cases a year. Though still predominantly a cancer that affects older people, cases among the under 50s have been increasing in recent decades.
Like many cancers, if bowel cancer is caught early the chances of a positive outcome are high. Nine in ten patients treated for stage one bowel cancer survive for five years or more, but specific sub-types of tumours don’t respond as well to treatment and are more likely to return. Five-year survival falls to 65% in stage three and 10% in stage four bowel cancer1.
In this trial, researchers from UCL recruited 32 patients with stage two or three bowel cancer and a certain genetic profile (MMR deficient/MSI-High bowel cancer) from five hospitals across the UK. Around 10-15% of patients with stage two or three bowel cancer have this particular genetic make-up, which represents around 2,000-3,000 cases per year in the UK.
Patients were given nine weeks of pembrolizumab prior to surgery instead of the usual treatment of surgery and chemotherapy, then monitored over time.
Results indicate that over 50% of patients treated with pembrolizumab had no signs of cancer after surgery. This compares to other studies where just 4% of patients treated with pre-operative chemotherapy then surgery had no signs of cancer after surgery.
All of the patients in the trial were still cancer-free many months later. The median cancer-free period was 9.7 months and ranged from 5.3 to 19 months among individual patients.
Over the next few years, the trial will also assess overall survival and relapse rates.
The approach also meant that patients did not require any post-operative chemotherapy, which has side effects and is tough to endure.
Dr Kai-Keen Shiu, Chief Investigator of the trial from UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, said: “Our results indicate that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers, increasing the chances of curing the disease at an early stage.
“We need to wait to see whether the patients in our trial remain cancer-free over a longer period of time, but initial indications are extremely positive. NEOPRISM-CRC is a trial that I first thought about in 2019 and am proud of my clinical and research teams at UCLH-UCL, as well as my co-investigators around the country who helped me create and deliver this study within 18 months of opening the trial in 2022. I am most of all thankful for the patients who participated in the trial so far and benefited from this treatment.”
The research also assessed whether tumour mutation burden could be a useful biomarker to predict individual risk.
Professor Mark Saunders, a Consultant Clinical Oncologist at The Christie, said: “This is a really very exciting new treatment for the 10-15% of patients who have the right genetic make-up. Immunotherapy prior to surgery could well become a ‘game-changer’ for these patients with this type of cancer. Not only is the outcome better, but it saves patients from having more conventional chemotherapy, which often has more side-effects.
“In the future, immunotherapy may even replace the need for surgery. However, more trials are needed to confirm these exciting early results and The Christie is delighted to collaborate in this way so that we can offer this new form of therapy to our patients as part of the NEOPRISM trial.”
Dr Marnix Jansen, a Clinician Scientist and Consultant Histopathologist who is leading the translational research on the trial from UCL Cancer Institute and UCLH, said: “More work needs to be done to assess pembrolizumab before it could be considered standard treatment, but given the quality of the outcomes in this trial I think it’s possible that we could see it in the clinic within a couple of years if subsequent trials are similarly successful.”
The NEOPRISM-CRC trial (NCT05197322) is funded by Merck Sharp and Dohme and is being conducted by the CR UK & UCL Cancer Trials Centre. The study is sponsored by University College London.
Clinical and research infrastructure and facilities at UCLH and UCL benefit from underlying support from the National Institute for Health and Care Research (NIHR) through the UCLH Biomedical Research Centre (BRC) and Clinical Research Facility (CRF).
Notes to Editors:
For more information, please contact:
Dr Matt Midgley
+44 (0)20 7679 9064
m.midgley@ucl.ac.uk
1 Cancer Research UK has more information about bowel cancer.
Publication:
Kai-Keen Shiu et al. ‘NEOPRISM-CRC: Neoadjuvant Pembrolizumab stratified to tumour mutation burden for High Risk Stage 2 or Stage 3 deficient-MMR/MSI-High Colorectal Cancer’ will be presented at ASCO 2024 and is strictly embargoed until Sunday 2 June at 14:00 BST / 09:00 ET.
About UCL – London’s Global University
UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.
Since 1826, we have championed independent thought by attracting and nurturing the world’s best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.
The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.
We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.
For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.
We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.
www.ucl.ac.uk | Follow @uclnews on Twitter | Read news at www.ucl.ac.uk/news/ | Listen to UCL podcasts on SoundCloud | View images on Flickr | Find out what’s on at UCL Minds
Method of Research
Randomized controlled/clinical trial
Subject of Research
People
